Health Care & Life Sciences » Pharmaceuticals | Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

Antibe Therapeutics Inc.
Stock Exchange Other OTC
EPS
$0.04
Market Cap
$60.1 M
Shares Outstanding
111.68 M
Public Float
-
Antibe Therapeutics Inc.
Stock Exchange Toronto Ventures Stock Exchange
EPS
CAD0.05
Market Cap
CAD78.5 M
Shares Outstanding
245.31 M
Public Float
201.67 M

Profile

Address
15 Prince Arthur Avenue
Toronto Ontario M5R 1B2
Canada
Employees -
Website http://www.antibethera.com
Updated 07/08/2019
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the research and development of medicines for pain and inflammation. Its lead drug, ATB-346, targets the need for a safer non-steroidal anti-inflammatory drug for treating chronic pain and inflammation with non-addictive medication. It operates through the Antibe and Citagenix segment.

Financials

View All

Daniel Legault
President, Chief Executive Officer & Director
Walter M. MacNee
Chairman